Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals, Inc. - Common Stock (NQ:AGIO)

28.32 -0.10 (-0.33%)
Streaming Delayed Price Updated: 10:58 AM EST, Nov 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agios Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out ↗
The stock is poised to break out of a cup-with-handle base after inking a deal for a cancer drug. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Attention Biotech Investors - Stocks To Watch ↗
RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences,... 
Via Benzinga
News headline image
Earnings Scheduled For February 15, 2024 ↗
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
News headline image
Earnings Preview: Agios Pharmaceuticals ↗
 
Via Benzinga
News headline image
RBC Capital Maintains Outperform Rating for Agios Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Agios Pharmaceuticals's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
AGIO Stock Earnings: Agios Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 ↗
AGIO stock results show that Agios Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
The 3 Best Biotech Stocks to Buy Now: Q2 Edition ↗
Investors can find some of the hottest, most explosive opportunities in these three top biotech stocks to buy now. 
Via InvestorPlace
News headline image
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark ↗
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84. 
Via Investor's Business Daily
News headline image
7 Biotech Stocks Fighting America’s Deadliest Diseases ↗
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship. 
Via InvestorPlace
News headline image
Why Is Blood Disorder Focused Agios Pharmaceuticals Stock Trading Higher Today? ↗
Agios Pharmaceuticals Inc (NASDAQ: AGIO) says the Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary  
Via Benzinga
News headline image
Agios Pharma Surges, And Retakes Its 200-Day Line, On Promising Test Results For Thalassemia Drug ↗
The company is working on an oral treatment for alpha and beta thalassemia. 
Via Investor's Business Daily
News headline image
Agios Pharmaceuticals's Return On Capital Employed Insights ↗
 
Via Benzinga
Agios Pharmaceuticals's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
It's time to dive into the biggest pre-market stock movers with all of the latest coverage worth reading about on Wednesday morning! 
Via InvestorPlace
News headline image
Agios Touts Encouraging Action From Sickle Cell Disease Study With Mitapivat ↗
Agios Pharmaceuticals Inc (NASDAQ: AGIO) announced that the Phase 2 portion of the global Phase 2/3 RISE UP study of mitapivat in sickle cell disease met its  
Via Benzinga
News headline image
Why Shares of Schrödinger Rose This Week ↗
Interest in the company's AI platform continues to drive the stock. 
Via The Motley Fool
News headline image
7 Biotech Stocks to Buy for 100% Returns ↗
If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio. 
Via InvestorPlace
News headline image
7 Biotech Stocks That Could Be the Next Big Thing ↗
Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023 ↗
 
Via Benzinga
News headline image
3 Under-the-Radar Biotech Stocks to Buy in 2022 ↗
The attraction of all three biotech stocks is their potential. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Europe Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency Patients ↗
 
Via Benzinga
News headline image
Agios Pharmaceuticals: Q3 Earnings Insights ↗
Agios Pharmaceuticals (NASDAQ:AGIO) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating ↗
Agios Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an increase from 65 to 93. 
Via Investor's Business Daily
News headline image
Why Snap Shares Jumped 7%; Here Are 75 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
News headline image
Why Okta Is Trading Lower By Over 32%, Here Are 58 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) jumped 94.4% to $27.24. ShiftPixy announced a 1-for-100 reverse stock split. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.